Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) traded up 4.3% on Wednesday . The company traded as high as $11.68 and last traded at $11.68, with a volume of 367,700 shares changing hands. The stock had previously closed at $11.20.

A number of equities research analysts have weighed in on the stock. Brean Capital reissued a “buy” rating and issued a $19.00 price target on shares of Momenta Pharmaceuticals in a report on Wednesday, May 4th. JPMorgan Chase & Co. reissued a “buy” rating on shares of Momenta Pharmaceuticals in a report on Wednesday, May 4th. Leerink Swann reissued an “outperform” rating and issued a $18.00 price target (down from $21.00) on shares of Momenta Pharmaceuticals in a report on Wednesday, May 4th. Zacks Investment Research raised shares of Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, April 27th. Finally, Goldman Sachs Group Inc. assumed coverage on shares of Momenta Pharmaceuticals in a report on Monday, June 6th. They issued a “neutral” rating and a $14.00 price target for the company. Six equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Momenta Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $18.40.

The firm’s 50-day moving average price is $11.24 and its 200 day moving average price is $10.61. The firm’s market cap is $798.36 million.

Momenta Pharmaceuticals (NASDAQ:MNTA) last announced its earnings results on Tuesday, May 3rd. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.32) by $0.03. The firm earned $19.90 million during the quarter, compared to the consensus estimate of $28.12 million. The business’s quarterly revenue was up 132.5% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.40) EPS. Analysts forecast that Momenta Pharmaceuticals Inc. will post ($1.33) earnings per share for the current fiscal year.

In other news, President Craig A. Wheeler sold 5,880 shares of the firm’s stock in a transaction on Friday, May 20th. The stock was sold at an average price of $10.18, for a total value of $59,858.40. Following the completion of the sale, the president now directly owns 349,521 shares in the company, valued at $3,558,123.78. The sale was disclosed in a filing with the SEC, which is accessible through this link.

A number of hedge funds have recently made changes to their positions in the company. Principal Financial Group Inc. raised its stake in shares of Momenta Pharmaceuticals by 4.6% in the fourth quarter. Principal Financial Group Inc. now owns 423,158 shares of the biotechnology company’s stock worth $6,279,000 after buying an additional 18,504 shares during the last quarter. Morgan Stanley raised its stake in shares of Momenta Pharmaceuticals by 123.0% in the fourth quarter. Morgan Stanley now owns 69,759 shares of the biotechnology company’s stock worth $1,035,000 after buying an additional 38,470 shares during the last quarter. GSA Capital Partners LLP raised its stake in shares of Momenta Pharmaceuticals by 298.9% in the fourth quarter. GSA Capital Partners LLP now owns 88,251 shares of the biotechnology company’s stock worth $1,310,000 after buying an additional 66,130 shares during the last quarter. New York State Common Retirement Fund raised its stake in shares of Momenta Pharmaceuticals by 2.0% in the fourth quarter. New York State Common Retirement Fund now owns 150,991 shares of the biotechnology company’s stock worth $2,241,000 after buying an additional 2,900 shares during the last quarter. Finally, Stevens Capital Management LP purchased a new stake in shares of Momenta Pharmaceuticals during the fourth quarter worth approximately $1,109,000.

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. It focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. It has developed generic version of Lovenox (enoxaparin sodium injection).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.